NEW YORK, NY / ACCESSWIRE / April 21, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
ANAB Shareholders Click Here: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?prid=6104&wire=1
I Shareholders Click Here: https://www.zlk.com/pslra-1/intelsat-s-a-loss-form?prid=6104&wire=1
GSX Shareholders Click Here: https://www.zlk.com/pslra-1/gsx-techedu-inc-loss-form?prid=6104&wire=1
* ADDITIONAL INFORMATION BELOW *
AnaptysBio, Inc. (NASDAQ:ANAB)
ANAB Lawsuit on behalf of: investors who purchased October 10, 2017 - November 7, 2019
Lead Plaintiff Deadline: May 26, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?prid=6104&wire=1
According to the filed complaint, during the class period, AnaptysBio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) AnaptysBio failed to disseminate important data from the Company's Phase 2a trial in atopic dermatitis, including the timing and extent of patients' use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company's Phase 2a trial in peanut allergy, including patients' average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company's decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants' positive statements about the efficacy and prospects of AnaptysBio's lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.
Intelsat S.A. (NYSE:I)
I Lawsuit on behalf of: investors who purchased November 5, 2019 - November 18, 2019
Lead Plaintiff Deadline: June 8, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/intelsat-s-a-loss-form?prid=6104&wire=1
The complaint filed against BC Partners, its individual partners and directors of Intelsat Raymond Svider and Justice Bateman, and Silver Lake Group, L.L.C. (and its related entities) alleges that throughout the class period, defendants made false and misleading statements to the market. Specifically, the complaint alleges that Silver Lake and its fellow defendants violated the Exchange Act by selling a block of Intelsat's shares while holding material non-public information, including the fact that the Company had met with the Federal Communications Commission (the "FCC") on November 5, 2019 to discussed the sale of spectrum controlled by Intelsat for future "5G" use (the "C-Band"). The FCC opposed Intelsat's proposal for a private sale of the C-Band, preferring a public auction. The FCC announced a public auction of the C-Band on November 18, 2019, contrary to Intelsat's wishes, its stock dropped 40%.
GSX Techedu Inc. (NYSE:GSX)
GSX Lawsuit on behalf of: investors who purchased June 6, 2019 - April 13, 2020
Lead Plaintiff Deadline: June 16, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/gsx-techedu-inc-loss-form?prid=6104&wire=1
According to the filed complaint, during the class period, GSX Techedu Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) GSX overstated its profitability, revenue, student enrollment figures, teacher qualifications, and teacher selection process; (ii) the foregoing, once revealed, was foreseeably likely to have a material negative impact on the Company's financial results; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP